| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5529766 | GE HEALTHCARE | Contrast agents |
Jun, 2013
(10 years ago) | |
| US6723303 | GE HEALTHCARE | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
Apr, 2021
(3 years ago) | |
Optison is owned by Ge Healthcare.
Optison contains Albumin Human.
Optison has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Optison are:
- US5529766
- US6723303
Optison was authorised for market use on 31 December, 1997.
Optison is available in injectable;injection dosage forms.
Optison can be used as ultrasound contrast agent.
The generics of Optison are possible to be released after 20 April, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-120) | Aug 17, 2015 |
Drugs and Companies using ALBUMIN HUMAN ingredient
Market Authorisation Date: 31 December, 1997
Treatment: Ultrasound contrast agent
Dosage: INJECTABLE;INJECTION
More Information on Dosage
OPTISON family patents
